-
Mashup Score: 69th Translational Research Conference: Myelodysplastic Syndromes | ESH - European School of Haematology - 3 month(s) ago
Chairs : Pierre Fenaux, Katharina Götze, Mikkael Sekeres SAVE THE DATE! April 12-14, 2024 – Budapest, Hungary Chairs: Pierre Fenaux, Katharina G ö tze, Mikkael Sekeres REGISTRATION & ABSTRACT SUBMISSION ARE OPEN! ABOUT THE CONFERENCE: ESH 9 th TRANSLATIONAL RESEARCH CONFERENCE ON MYELODYSPLASTIC SYNDROMES proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international
Source: www.esh.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Metrics by Which We Measure Quality: From Questions to Psychological Safety | ASH Clinical News | American Society of Hematology - 3 month(s) ago
Aaron Gerds, MD, is the deputy director for clinical research at Cleveland Clinic Taussig Cancer Institute and associate professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve Uni versity. Faster than a speeding IV pole, more predictable than Haley’s comet, able to induce somnolence in a post-call fellow with a single PowerPoint slide. What used to be a nascent administrative agenda item is now the main attraction: the quality meeting. Although providing the best and safest care
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Opinion | When a Revolutionary Cancer Treatment Causes Cancer - 3 month(s) ago
The potential benefits of CAR T-cell therapies still far outweigh the risks
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Opinion | When a Revolutionary Cancer Treatment Causes Cancer - 3 month(s) ago
The potential benefits of CAR T-cell therapies still far outweigh the risks
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 69th Translational Research Conference: Myelodysplastic Syndromes | ESH - European School of Haematology - 3 month(s) ago
Chairs : Pierre Fenaux, Katharina Götze, Mikkael Sekeres SAVE THE DATE! April 12-14, 2024 – Budapest, Hungary Chairs: Pierre Fenaux, Katharina G ö tze, Mikkael Sekeres REGISTRATION & ABSTRACT SUBMISSION ARE OPEN! ABOUT THE CONFERENCE: ESH 9 th TRANSLATIONAL RESEARCH CONFERENCE ON MYELODYSPLASTIC SYNDROMES proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international
Source: www.esh.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 54Drugs and the FDA: Safety, Efficacy, and the Public's Trust - 4 month(s) ago
Drugs and the FDA: Safety, Efficacy, and the Public’s Trust
Source: www.amazon.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Matthew Matasar, MD, is a medical oncologist specializing in lymphoma and is chief of the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. When I last was up for recertification for medical oncology, I realized with a sense of long-suppressed dread that I was going to fail. After all, I’m an academic oncologist who focuses on one thing and one thing only — lymphoma — and that’s not good when it comes to the boards. Hematologic malignancies make up a whopping
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Matthew Matasar, MD, is a medical oncologist specializing in lymphoma and is chief of the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. When I last was up for recertification for medical oncology, I realized with a sense of long-suppressed dread that I was going to fail. After all, I’m an academic oncologist who focuses on one thing and one thing only — lymphoma — and that’s not good when it comes to the boards. Hematologic malignancies make up a whopping
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Matthew Matasar, MD, is a medical oncologist specializing in lymphoma and is chief of the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. When I last was up for recertification for medical oncology, I realized with a sense of long-suppressed dread that I was going to fail. After all, I’m an academic oncologist who focuses on one thing and one thing only — lymphoma — and that’s not good when it comes to the boards. Hematologic malignancies make up a whopping
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51
Matthew Matasar, MD, is a medical oncologist specializing in lymphoma and is chief of the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. When I last was up for recertification for medical oncology, I realized with a sense of long-suppressed dread that I was going to fail. After all, I’m an academic oncologist who focuses on one thing and one thing only — lymphoma — and that’s not good when it comes to the boards. Hematologic malignancies make up a whopping
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
RT @ESHaematology: 🙌 THE PRELIMINARY PROGRAMME OF #ESHMDS2024 IS AVAILABLE Read it NOW ➡ https://t.co/srVk8TI3Y1 🗓️ April 12-14, 2024 in Bu…